U.S. Gene Therapy Market 2030: Pioneering Treatments for Rare Diseases
The U.S. gene therapy market was valued at USD 3.11 billion in 2023 and is projected to reach USD 10.40 billion by 2030, growing at a compound annual growth rate (CAGR) of 19.21% from 2024 to 2030. Gene therapy encompasses DNA-based treatments that deliver a functional copy of a faulty gene or correct a mutated gene using viral vectors, plasmids, or gene editing tools. A robust development pipeline, led by universities and research institutions, is anticipated to significantly contribute to revenue generation over the coming years. Despite some delays in clinical trials caused by the COVID-19 pandemic, the crisis underscored the potential of gene therapy for both prevention and treatment of diseases, leading to greater funding and investment in this space. While the pandemic temporarily slowed trial progression, it also amplified global interest and focus on the field. Technological advancements have played a critical role in transitioning gene therapy from experimental stages to cl...